Showing results (141-150 of 153) with videos related to
Sort By:
Pageof 16
ACS Medicinal Chemistry Letters|November 19, 2021
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical CandidateRobert J Cherney, Prakash Anjanappa, Kumaravel Selvakumar, et al.American Journal of Human Genetics|March 1, 1997
A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndromeM Muenke, K W Gripp, D M McDonald-McGinn, et al.Bioorganic & Medicinal Chemistry Letters|February 10, 2020
Discovery and SAR of aryl hydroxy pyrimidinones as potent small molecule agonists of the GPCR APJMichael C Myers, Donna M Bilder, Cullen L Cavallaro, et al.Breast Cancer Research and Treatment|August 11, 2018
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancerAdrienne E Borrie, Rhiannon V Rose, Yun-Hee Choi, et al.Analytical Biochemistry|January 4, 2019
Linking (Pyr)1apelin-13 pharmacokinetics to efficacy: Stabilization and measurement of a high clearance peptide in rodentsJoelle M Onorato, Carrie Xu, Xue-Qing Chen, et al.Journal of Medicinal Chemistry|May 28, 2025
The Discovery of C7-Substituted Norbornyl Bisamides as RXFP1 Small Molecule AgonistsShun Su, Michael C Myers, Donna M Bilder, et al.ACS Medicinal Chemistry Letters|April 21, 2015
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5Percy H Carter, Gregory D Brown, Robert J Cherney, et al.ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2Michael G Yang, Zili Xiao, Rulin Zhao, et al.Nature Communications|July 14, 2025
Pulses of ocean acidification at the Triassic-Jurassic boundaryMolly Trudgill, James W B Rae, Ross Whiteford, et al.Journal of Medicinal Chemistry|August 8, 2014
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritisJoseph B Santella, Daniel S Gardner, John V Duncia, et al.Pageof 16